Speaking to CNBC-TV18 on the company’s third quarter performance and the outlook going forward, Uday Baldota, CFO, Sun Pharma said they are hopeful of meeting the FY15 topline growth guidance of 13-15 percent and are not changing the guidance at the moment. The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward. Margins in Q3 were high on back of high Taro margins and because of few products in the US. The company is eagerly waiting for the Punjab & Haryana High Court (HC) approval for the Ranbaxy nerger, said Baldota.
No comments:
Post a Comment